Blue Shield of California covers Wegovy only in narrow circumstances. Since January 1, 2025, the insurer has required prior authorization for Wegovy on its commercial HMO and PPO plans, and approval generally requires a diagnosis of Class III (morbid) obesity, meaning a BMI of 40 or higher, together with active participation in a comprehensive weight loss program. Medicare Advantage plans exclude Wegovy for weight loss entirely, Medi-Cal has dropped coverage for adults, and employer plans vary based on the pharmacy rider the employer selected. If you don’t clear the bar, you pay the full price.
The 2025 Prior Authorization Rule
Blue Shield announced the policy change in November 2024. Effective January 1, 2025, or upon plan renewal after that date, Wegovy became one of 13 weight loss drugs that require prior authorization demonstrating medical necessity on commercial HMO and PPO plans. Members who already had a valid prior authorization could continue filling their prescriptions until that authorization expired.1Blue Shield of California. Weight Loss Medication Coverage Change Fact Sheet
To get approval, the member must have a current or previous diagnosis of Class III (morbid) obesity. The member must also be participating in a comprehensive weight loss program that includes a reduced-calorie diet, physical activity, and behavior therapy, both before starting Wegovy and while taking it.1Blue Shield of California. Weight Loss Medication Coverage Change Fact Sheet
Without that documentation, the plan treats Wegovy as excluded and the member pays out of pocket. Providers and members can verify the current authorization requirements through Blue Shield’s Provider Connection website or by calling Provider Services at (800) 541-6652.
How the Answer Depends on Your Plan
Individual and Covered California Plans
For individual and family plans, including those bought through Covered California, the 2025 rule applies directly. Wegovy is excluded unless prior authorization confirms medical necessity for Class III obesity.2Blue Shield of California. Silver 70 Off-Exchange Trio HMO Summary
Employer Plans
Employer coverage is where the answer gets slippery. Blue Shield offers large group commercial plans with a menu of prescription drug riders, and only one option, called Enhanced+ Rx, includes enhanced coverage for weight loss drugs. The Basic Rx, Enhanced Rx, and Premier Rx riders do not appear to include it.3Blue Shield of California. Large Group Prescription Drug Riders
Starting January 1, 2026, Blue Shield told providers that weight loss drug coverage on large group commercial plans “will vary.” Depending on the plan, the BMI threshold for newly prescribed weight loss drugs may be 40 or higher, 30 or higher, or 27 or higher with certain conditions. Some employers may choose to offer no weight loss drug coverage at all.4Blue Shield of California. Provider News and Education
Two people with Blue Shield through work can get different answers. Check the plan’s summary of benefits or call the number on your member ID card before assuming either way.
Medi-Cal
California’s Medi-Cal program, which Blue Shield administers in several counties, discontinued coverage of GLP-1 medications prescribed for weight loss or weight-related indications for adults 21 and older effective January 1, 2026. Wegovy is classified as a weight loss medication and is not covered under the standard benefit for adults. Prior authorization requests may still be considered for noncirrhotic MASH or cardiovascular disease, and enrollees under 21 may still qualify for weight-loss GLP-1 therapy through prior authorization.5CMA Docs. GLP-1 Medications for Weight Loss Will No Longer Be Covered by Medi-Cal
Medicare Advantage
Blue Shield’s Medicare Advantage and Medicare prescription drug plans exclude drugs used for weight loss from their formularies.6Blue Shield of California. Medicare Formularies That reflects a federal ban dating to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, which prohibits Part D plans from covering anti-obesity medications under the standard drug benefit. Wegovy is covered under Part D when prescribed for a different FDA-approved indication, such as cardiovascular risk reduction or MASH.7AARP. Does Medicare Cover Ozempic, Wegovy, and Other Weight Loss Drugs
A temporary federal program, the Medicare GLP-1 Bridge, runs from July 1, 2026 through December 31, 2027. It offers eligible Medicare beneficiaries Wegovy, Zepbound (KwikPen), and Foundayo for weight management at a fixed $50 copay per monthly fill. The program runs outside standard Part D, so Blue Shield does not need to opt in for its Medicare Advantage members enrolled in an MA-PD coordinated care plan to participate. Prior authorization requests are processed centrally by Humana rather than the member’s Part D plan.8CMS. Medicare GLP-1 Bridge
To qualify, beneficiaries must be at least 18, use the medication with lifestyle modifications, and meet one of these BMI-plus-diagnosis criteria:
- BMI of 35 or higher, with no additional diagnosis required.
- BMI of 30 or higher with heart failure (preserved ejection fraction), uncontrolled hypertension, or chronic kidney disease stage 3a or higher.
- BMI of 27 or higher with pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease.
The $50 copay doesn’t count toward Part D deductibles or out-of-pocket limits, and Extra Help cannot be applied to it.9CMS. Medicare GLP-1 Bridge – Information for Providers10Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026
What You Pay If Blue Shield Says No
The list price for Wegovy runs about $1,350 for a 28-day supply, roughly $16,200 a year. Novo Nordisk offers reduced self-pay pricing through its direct channel: the 1.5 mg and 4 mg doses are $149 per month through August 31, 2026, after which the 4 mg dose rises to $199. Starter doses (0.25 mg and 0.5 mg) run $199 per month for the first two months, then $349 per month.11Wegovy. What to Pay for Wegovy
Novo Nordisk also offers a savings card that can bring copays as low as $25 per month for patients whose commercial insurance does cover Wegovy, with a maximum savings of $100 per fill. Patients on Medicare, Medicaid, Tricare, or other government programs cannot use the card.11Wegovy. What to Pay for Wegovy
Appealing a Denial
If Blue Shield denies your Wegovy request, you have several routes:
- File an internal grievance within 180 days of the denial. You can submit online, by mail, or by calling (800) 393-6130. Standard grievances are resolved within 30 calendar days; expedited appeals for urgent health risks are resolved within three calendar days.
- Request an Independent Medical Review (IMR) if the denial rests on medical necessity. This is a free external review, and the internal appeal generally must come first. Failing to request an IMR when eligible may forfeit your right to sue over the denied service.
- Contact the California Department of Managed Health Care at (888) 466-2219 or through dmhc.ca.gov if the internal grievance is unresolved after 30 days or involves urgent care.
You can appoint a physician, attorney, family member, or friend to act on your behalf using Blue Shield’s Appointment of Representative form.12Blue Shield of California. Grievance Process
The appeals path is worth taking seriously. In a 2025 enforcement action, the DMHC found that Blue Shield violated the Knox-Keene Act after denying a Wegovy refill even though medical records confirmed the member’s weight and adherence to the diet, exercise, and behavioral requirements. One Blue Shield response upheld the denial for lack of medical necessity while simultaneously telling the member that an internal specialist had approved the request; the plan acknowledged it had “overlooked” the peer review report during the grievance process. The medication was authorized nearly two months after the initial request. Blue Shield agreed to a $30,000 penalty in a settlement signed in August 2025.13DMHC. Enforcement Matter No. 24-732
Pending California Legislation
No California law currently requires health insurers to cover anti-obesity medications. Assembly Bill 575, the Obesity Prevention Treatment Parity Act, would have required plans to cover at least one FDA-approved anti-obesity medication (including GLP-1 drugs) and would have eliminated prior authorization. It failed in February 2026.14LegiScan. California AB575 Amended
Senate Bill 1089, the Preventive Treatment Health Care Act, is still moving. As of June 2026 it was re-referred to the Assembly Appropriations Committee. In its current form the bill would require CalPERS health plans, not commercial Blue Shield plans or Medi-Cal, to cover at least one FDA-approved GLP-1 medication for chronic weight management from January 1, 2028 through 2032.15CalMatters Digital Democracy. SB 1089